CLDN18 and neoplasm: Quantification analysis of signal intensity from the tumors demonstrated that Nano/CLDN18.2 and NanoBE exhibited significantly higher accumulation compared to Nano/TM and Nano/CD40 (Fig. 3b), highlighting the pivotal role of anti-CLDN18.2 scFv in tumor targeting.